预约演示

Basilea sells rights to microtubule drug to Glioblastoma Foundation Glioblastoma Foundation

2024-06-20

交易

孤儿药临床结果临床2期ASCO会议

Basilea joined an asset purchase agreement for its brain cancer therapy following a negative Phase II study. Credit: Taljat David via Shutterstock.

Basilea has signed an asset purchase agreement withbrain cancerstoma Foundation for the company’s glioblastoma candidate, lisavanbulin (BAL101553).

Basileahe terms of the deal, Basilea will sell and transGlioblastoma Foundationvanbulin to the chaglioblastomanisation forlisavanbulinseBAL101553 purchase cost. In the future, Basilea will continue to take part in any potential commercial partnerships at a fixed double-digit percentage. The Glioblastoma Foundation plans to take over lisavanbuilin’s post-access trial programme, allowing patients from previous clinical studies to continue receiving the drug. The charity will also oversee any further clinical studies investigating the use of lisavanbulin in glioblastoma.

Lisavanbulin is a checkpoint Basileaor that binds to tubulin, which blocks lisavanbulinle and triggers cell death in cancer cells. The company was developing the drug for brainBasilea, and the drug even received an US Food and Drug Administration orphan drug designation in 2021 for the treatGlioblastoma Foundationa, a type of brain cancer.lisavanbulin glioblastoma

Lisavanbuliner a disappointing Phase I/II trial (NCT0tubulin) readout, the Swiss pharmaceutical company decided not tcancernd the glioblastoma patient cohort for lisavanbubrain cancer In the open-label study of nine paFood and Drug Administrationse at stage one, one patient demonstrated a partial remalignant gliomanbulin whilsbrain cancerowed a 44% target lesion area reduction, as per an American Society of Clinical Oncology 2023 abstract. However, despite sustained activity in these subjects, they were unable to meet formal stage transition criteria leading to an early study completion.

Glioblastomas are fast-growing brain tumours that are commonly treated through surgery radiotherapy and chemotherapy. According toglioblastoman Brain Tumor Associlisavanbulinlastomas make up approximately 14% of all primary brain tumors, with 12,000 cases diagnosed each year in the US.lisavanbulin

See Also:AZD-1705 by AstraZenecbrain tumoursdemia: Likelihood of ApprovalBrain Tumor glioblastomas primary brain tumors

SabestomiAZD-1705raZeAstraZenecaohn’sDyslipidemiagional Enteritis): Likelihood of Approval

In a 20 June press release, Dr Gita Kwatra, the Glioblastoma Foundation’s CEO, said, “We strongly believe that lisavanbulin will be effective in a subset of glioblastoma patients and we are looking forward to initiating clinical trials of lisavanbulin in the US.”

The recent annAstraZenecaarks Crohn’s Diseased Regional Enteritisdeal of 2024. In January 2024, the company signed an agreement with Spexis to acquire its preclinical antibiotics programme. Before this, in October 2024, Basilea sought out a partner for its antibiotic ceftobiprole.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构